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Although there are a number of weaknesses for clinical use, pluripotent stem cells are valuable sources for patient-speciﬁc cell
therapies against various diseases. Backed-up by a huge number of basic researches, neuronal diﬀerentiation mechanism is well
established and pluripotent stem cell therapies against neurological disorders are getting closer to clinical application. However,
thereareincreasingneedsforstandardizationofthesourcingpluripotentstemcellsbyestablishingstemcellregistriesandbanking.
Global harmonization will accelerate practical use of personalized therapies using pluripotent stem cells.
1.Introduction
Infectious diseases have been life-threatening with the aid of
newly emerging ones caused by environmental and sociocul-
tural changes of human life. However, coping with infectious
agents is being accelerated and accurate by scientiﬁc achieve-
ment resulting in antibiotics and vaccines development, so
that importance of managing physical damages caused by
external wound or physiological disorders of internal origin
is being important in the present.
Approaches to cure the wound-mediated loss of physical
function or genetic disorders had been focused on preven-
tion from worsening of damage to deteriorate neighboring
tissue or organs using medicinal and surgical eﬀorts. Along
the 20th century’s era of organ transplantation, recent ap-
proaches of regenerative medicine using stem cell are emerg-
ing as a sensation in biomedical sciences in 21st century and
provoking an innovative development in medicine.
It is expected that personalized regenerative medicinal
approach using stem cells will be accelerated by continuous
huge investment and research eﬀorts throughout the world.
Since human embryonic stem cell (hES) was ﬁrst established
in 1998 [1], researches to establish pluripotent stem cells,
that is, ES cells, or isolate stem cells from various adult
tissue or organs and to diﬀerentiate them into target tissues
of therapeutic interest such as neuronal, cardiovascular,
pancreatic, and hepatic lineages have been progressed and
the possible outcomes are expected to be utilized as person-
alized therapeutics and as basic research tools for disease
modeling. Although there are still challenges for practical
application of stem cell therapies in clinical use in the
present, however, the growing number of clinical trials for
therapies using adult stem cells of various human tissue
origin as well as hES cells is increasing public expectation for
practical use of stem cell therapies in regenerative medicine
(http://www.clinicaltrial.gov/). Here we reviewed what is
current status of personalized therapies for neurological
disorders using pluripotent stem cells and what is needed to
further expand their application in practical use.
2.PluripotentStemCells asSources for
Personalized Stem Cell Therapy
Pluripotent stem cells have inﬁnite proliferative potential
and capacity to diﬀerentiate into three germ layer-derived
cell types of a body: ectoderm, endoderm, and mesoderm.
Pluripotent stem cells comprise ES cells and, more recently,
induced pluripotent stem (iPS) cells.
ES cells are derived from the inner cell mass of blastocyst
[1]. ES cells can generate all type cells of three germ layer2 Journal of Biomedicine and Biotechnology
origin while adult stem cells are thought to be limited in dif-
ferentiation potential into various cell types of tissue origins.
In comparison to adult stem cells which have limitation in
ex-vivo proliferation, ES cells can be grown indeﬁnitely in
cell culture of optimized condition. With those natures, ES
cells are beneﬁcial as a source of cell replacement therapies
for supplying a large number of cells needed for therapeutic
application stably.
The iPS cells are reprogrammed from somatic cells by
introduction of a number of ES cell-speciﬁc genes, mainly
OCT4, SOX2, KLF-4, C-MYC, LIN28, and NANOG. The
introduction of iPS cell by Shinya Yamanaka brought huge
scientiﬁc interest into stem cell and regenerative medicine
ﬁeld because of biomedical and socioeconomical impacts of
iPS cells [2–5]. Until now the technical improvement related
to iPS cells generation is ongoing by using diverse cell types,
diﬀerent factors, and various methods [4–6].
Major advantages of iPS cells can be described by two
aspects. First, the method of iPS cell establishment is free
of ethical concern by which hES cells are critically screened
before utilizing in research. Second, iPS cells are patient-
speciﬁc source of pluripotent stem cell because the cells
are originated from patients’ somatic cells by introducing a
number of ES-speciﬁc genes [2, 3, 7]. So to speak, patient-
speciﬁc iPS cells are unlimited source of autologous stem cell
therapy with perfect match of leukocyte antigen, and then
we may overcome a hurdle of graft versus host interaction.
Moreover, somatic cells from patients with genetic disorders
have been reprogrammed to make iPS cells and then dif-
ferentiated into disease-speciﬁc tissues for modeling, inves-
tigating disease pathophysiology and then drug discovering
[8–10].
However, there are a number of reports for limitations
of current technologies that hinders iPS cells into practical
use. First, increase of tumor formation possibility is reported
[11, 12]. Introduction of c-MYC protooncogene as one
of reprogramming factors increases tumor formation. In
addition, retro or lentiviral transduction of reprogramming
factors causes not only epigenetic reconﬁguration but also
genetic modiﬁcation which may lead to cancer formation
[13, 14]. Second, it was reported that mouse iPS cells have
immunogenicity to syngeneic recipient. This suggests that,
although iPS cells are conceived to be immune-tolerated to
autologous recipients, there are still hurdles to overcome to
establishmoreES-likeiPScellsintermsofcompleteness[15].
Supported by the numerous research milestones for the
achievement in pluripotent stem cells both hES and iPS cells,
their clinical usage is being realized. A couple of clinical
trials are undergoing (http://www.clinicaltrial.gov/); how-
ever, practical application of pluripotent stem cells is mainly
being evaluated at the level of research and development.
In order to solve remained controversy and problems many
basic issues left to be done: to understand how to control
stem cell proliferation and diﬀerentiation into speciﬁc cell
types, to enhance survival in recipient, to prevent immune
rejection and induce their integration into recipient cellular
network,andtooptimizethefunctionalrecoveryofdamaged
tissue or organs in human disease. In addition, the use
of pluripotent stem cells should solve the problems of the
immunerejectionofgraftedstemcellsandtumorformations
in cell replacement therapy.
3. Historical Aspect of PersonalizedTherapies
UsingStemCellsinNeurologicalDisorders
As above mentioned, stem cells have promised to revo-
lutionize the future of regenerative medicine through the
cell replacement therapies to treat a variety of deliberating
diseases. Although using pluripotent stem cell for treatment
is relatively new, convincing evidence has emerged the
capabilityofvariousstemcellpopulationsusedfortreatment
of various diseases. The applications of stem cell therapies
for treating neurological disorders are enormous. Mimicking
the neural stem cell activity, the treatment of neurological
disorders is based on the ideas that the replacement of
damaged cells and the restoration of brain homeostasis can
be achieved through transplantation of stem cell. Many
laboratories have attempted stem cell treatment for central
nervous system diseases, including spinal cord injury, stroke,
amyotrophic lateral sclerosis, Parkinson’s diseases, multiple
sclerosis, and epilepsy [16–22].
The ﬁrst nonhematopoietic bone marrow-derived mul-
tipotent stromal cells (BMSC) were reported in 1976 [23].
From the beginning, BMSCs were focused for cell therapy
because they are easily obtained from human bone marrow
aspirates, rapidly expanded in culture. Moreover, it was
reported that BMSCs can be used autologously and do not
form tumors after transplantation [24]. In recent report, the
clinical trial for strokes with intravenous BMSC treatment
long-term follow-up showed that the improved survival
statics compare with control [25].
Fetal Neural Stem Cells (NSCs) can be derived from
human fetal brain and capable of diﬀerentiating into neu-
rons, astrocytes, and oligodendrocyte [26]. The fetal NSCs
are generally isolated from abortus and their use is conceived
less ethically controversial than hES cells. There is available
evidence that supports eﬃciency of intrastriatal trans-
plantation of human embryonic mesencephalic tissues in
Parkinson’s disease. These studies demonstrated that grafted
dopamine neurons can survive, reinnervate the striatum,
and restore dopamine release for up to 10 years despite
an ongoing disease progress, which destroys Parkinson’s
disease patient’s own dopamine neurons [27, 28]. However,
a number of recent postmortem studies examined long-
term fetal transplants in Parkinson’s diseases have revealed
that host pathogenic factors aﬀect the transplants and
their recipients [29–31]. The long-term clinical follow-up
in six individuals who survived 9–16 years after the fetal
neuronal tissue transplantation showed that the eﬀect of
transplantation is limited and three of them showed typical
brain pathology of Parkinson’s diseases at autopsy [29–31].
These indicate that the engrafted cells may be aﬀected by
the disease process of the recipients weakening the long-term
clinical beneﬁts as a therapeutic approach.
Over the last decade, there has been a rapid advance
in research of pluripotent stem cells including ES and iPS
cells. Many studies suggested that ES cells have the ability
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including neural progenitor, neurons, oligodendrocyte, and
astrocyte [32–37]. In addition, accumulating data have prov-
en the therapeutic eﬃcacy of hES cell-derived neural precur-
sor cells (NPCs) in experimental model of neurological dis-
eases [33, 34, 38, 39]. Recently a number of reports showed
the use of iPS cells to treat several neurological disorders
such as Parkinson’s and Huntington’s disease, spinal mus-
cular atrophy, amyotrophic lateral sclerosis, and spinal cord
injuries [4, 21, 40, 41].
The generation of iPS cells from a somatic cell having
genetic disease patients oﬀers the opportunity to disease
modeling and possibility for treatment in personalized cell
therapy by accelerating drug discovery. Patient-speciﬁc iPS
cells from degenerative neurological diseases such as familial
dysautonomia [8] and adrenomyeloneuropathy [42]o p e n e d
possibility to comprehend disease mechanism and discover
drug to moderate symptoms.
4.In Vitro Differentiation into
NeuralLineagefrom ESCells
Establishment of eﬃcient and stable in vitro method for
neural diﬀerentiation is an important preceding process for
clinical application of pluripotent stem cells [43]. Character-
istically, nervous system is composed of heterogeneous pop-
ulations mixed with a variable cell types including neurons,
astrocytes, oligodendrocytes, and their precursor cells [44].
To make these variable neural components during normal
development, a part of ES cells undergoes neural induction
and rostrocaudal and dorso-ventral patterning. Throughout
these steps, human nervous system is assorted by forebrain,
midandhindbrain,andspinalcord.Afterthentemporaland
spatial patterning is followed, resulting in diﬀerentiation of
cortical progenitor cells into generate subtypes of neurons
and formation of cortical structures with six layers. Each
subtype of neurons has its own speciﬁc function and its
damages and defects are associated with diﬀerent types of
diseases or disabilities, undoubtedly [45]. Many previous
researchers have tried for eﬃcientderivationofmanymature
cell lines from pluripotent stem cells. Unfortunately, in
vitro diﬀerentiation process cannot be always reﬂected to
in vivo diﬀerentiation steps in neurogenesis. Additionally
transcriptional variability between the hES cell lines and
also their diﬀerentiated neural cells is remained, reﬂecting
the heterogeneity in the way the ES cells were established
[46]. Here, we introduce and summarize the representative
protocols and mechanisms of the neural diﬀerentiation from
the pluripotent stem cells.
In vitro neural diﬀerentiation of pluripotent stem cells
involves three main stages of neural induction, expansion of
neural progenitor cells, and diﬀerentiation to neurons and
glial cells [47, 48].
In earliest procedures for neural induction, hES cells
were led to spontaneous diﬀerentiation into embryoid body
and then neural progenitor cells appearing rosette-like struc-
tures were mechanically isolated [36]. With identiﬁcation
of various diﬀerentiation-related cellular mechanisms and
pathways, the inhibition of bone morphogenetic proteins
(BMPs) and/or SMAD signaling pathways is known to be
necessary for eﬃcient induction of neural induction of hES
cells. BMPs are members of transforming growth factor-beta
(TGFβ) and activate the speciﬁc type I and type II receptors,
leadingtophosphorylationoftheirdownstreamSMAD[47].
Usingthismechanism,Chambersetal.[49]havedesignedan
eﬃcient protocol for neural conversion from one ES and two
iPS lines. They treated with recombinant Noggin and drug
SB431542 for combined dual inhibition of SMAD signaling
andidentiﬁedexpressionofneuroectodermalmarkers,PAX6
and SOX2, in mRNA and protein levels [49]. Another
study demonstrated that hES cells can diﬀerentiate into the
Pax6+/Sox1+ neural rosette in the presence of noggin and
supplemental addition of ﬁbroblast growth factor (FGF)
[50]. Additionally, inhibition of FGF signaling pathway led
to impairment of neural induction, suggesting that FGF
signaling can implicate in the neural speciﬁcation stages
independently of BMP signaling [51]. More recently, it is
found that coincident blockade of Activin/Nodal and BMP
pathways by SB431542 and dorsomorphin enhances the
neural diﬀerentiation in variable pluripotent stem cell lines.
An advantage of this protocol is that the diﬀerentiation
eﬃcacy is constant neural regardless of the divergence [48].
Following neural induction, neural expansion process
should be announced. In this stage, the neural precursor
cells in EBs are expanded in suspension culture with media
usually containing mitogenic factors, such as bFGF or
epidermal growth factor (EGF) [47, 48]. WNT signaling
pathway is thought to be contributed for formation and
maintenance of hES cell-derived neurosphere in this stage
[52].
In the next stage, hES cell-induced and -expanded neural
progenitor cells are diﬀerentiated into neural or glial cells.
Plating of the precursor cells on the laminin, ﬁbronectin or
matrigel substrates promotes diﬀerentiation of the precursor
cells to neurons and glia. In addition, absence of previously
treated mitogenic factors helps their diﬀerentiation process
into mature cell lines [47, 48]. A study found that the
determination of the cell lineages is governed by combined
activation of some signaling pathway including Rho/ROCK
and PI3K/Akt pathways [47].
The ﬁnal stage of the in vitro neural diﬀerentiation
process is a neural speciﬁcation that means terminal dif-
ferentiation of immature cells into full matured cells with
acquisitionoftheirowntypicalcellularfunctions.Combined
treatment of various cytokines in mid-stage neural cells
makes various types of mature function-speciﬁc neural cells.
It is very important to reveal how to diﬀerentiate to a speciﬁc
neural cell lineage for replacement therapy using ES cells as a
substitution of abnormal or malfunctioning cells. Selective
loss of dopaminergic neurons in the substantia nigra is
a characteristic of Parkinson’s disease and many studies
have developed the methods for diﬀerentiating from ES
cells to mature dopaminergic neurons [36]. Both Shh and
FGF8 are considered as important ligands for production of
dopaminergic neurons. Biologic eﬀects of these molecules in
neurogenesis support the evidence of addition of Shh and
FGF8 in the culture media that have been applied in most
previous described protocols [36, 53, 54]. For diﬀerentiation
into glial lineages, treatment of FGF2 followed by treatment4 Journal of Biomedicine and Biotechnology
of PDGF, IGF, NT3, and Shh generates oligodendrocytic
diﬀerentiation of hES cells [55]. Another glial cell types,
mature astrocytes, can be produced from hES cells by using






sion in the absence of changes in DNA sequence. Epigenetic
events include DNA methylation, histone modiﬁcation, and
nucleosome remodeling, leading to structural changes of
chromatin and subsequent transcription regulation [57].
Polycomb group proteins (PcG) are representative regulators
of epigenetic changes and they are conservative components
from Drosophila to humans. Structurally they form distinct
multimericcomplexes,calledPolycombrepressivecomplexes
(PRCs), classiﬁed as two groups, PRC1 and PRC2. PRC2 is
composedofEZH2,SUZ12,andEED,whichactsasinitiators
of transcription inhibition [58]. PRC1 can recognize the
trimethylates lysine 27 occurred by PRC2 through the chro-
modomain and maintain the gene repression status [59].
The expression of ES cell and their development-related
genes are modiﬁed by epigenetic regulatory factors [60].
PcG is known to be an essential constituent for maintaining
the properties of ES cells by regulation of the transcription
factors OCT4, SOX2 and NANOG, all that are expressed in
undiﬀerentiated status and are associated with ES cell self-
renewalandpluripotency[58].Asdiﬀerentiationprogressed,
pluripotent genes including OCT4, SOX2, and NANOG are
downregulated by methylation on the promoter region [61].
On the other hand, diﬀerentiation-related genes expressing
in hematopoietic stem cells and neural progenitor cells
are activated by demethylation of their promoter region
[58]. PRCs also play crucial roles as inhibitors of diﬀer-
entiation. Using genetic ontology, a study demonstrated
that the functions of PcG-binding genes in hES cells are
involved in development, transcription regulation, organo-
genesis and neurogenesis. Hox, GATA, NeuroD, FOX, POU,
and MYO are controlled by PcG and it means that PcG
represses the expression of diﬀerentiation-promoting genes.
This study demonstrated that SUZ12 occupies a subset of
diﬀerentiation-promotinggenesalsoboundbyOCT4,SOX2,
and NANOG in hES cells [58]. Another study revealed that
when ES cells experienced spontaneous diﬀerentiation form-
ing embryoid body (EB), PcG-binding genes are speciﬁcally
activated in diﬀerentiated state or EBs [61]. PcG can closely
anddelicatelyregulatetheexpressionofbothpluripotentand
diﬀerentiated genes to proper development.
In in vivo studies, PcG also is proven to be concerned
in organogenesis and diﬀerentiation of pluripotent stem
cells. PRC2 subunits (Eed, Ezh2, Suz12) knockout mice
suﬀered a congenital defect in gastrulation [62–64]. EED or
Suz12 knockout murine ES cells showed decreased H3K27
m e t h y l a t i o na sw e l la sa b n o r m a l l yi n c r e a s e de x p r e s s i o n
of diﬀerentiation-related genes, suggesting the epigenetic
changes produced by Eed, Suz12 and histone methylation
contribute the diﬀerentiation process [63, 65, 66]. Another
study revealed that Suz12 knockout murine ES cells fail to
achievetheprimaryneuroepithelialdevelopment[66].Thus,
epigenetic regulation is necessary for appropriate develop-
ment and diﬀerentiation on pluripotent stem cells.
Neural diﬀerentiation from ES cells is also eﬀected by
epigenetic events,suchasmethylation oracetylation. Among
the epigenetic events, H3K4 trimethylation and H3K9
methylation were found to play roles in repressing the
pluripotency- and diﬀerentiation-associated genes during
neurogenesis from hES cells, respectively [67]. Moreover,
Bmi-1, one of the polycomb group proteins, allows main-
taining the self-renewal and proliferation of neural stem
cells. Bmi-1 knockout neural stem cells have a decreased
clonogenic capacity and proliferative index, in which epige-
netic change is implicated in maintaining stemness [68–71].
AnotherPcG,Ring1B,isalsoconcernedwithmaintenanceof
pluripotency and self-renewal in ES stem cell-derived neural
precursor cells. Ring 1B deﬁcient ES cell-derived neural
stem cells show a decreased eﬃcacy and size of neurosphere
formation as well as increased neural induction [68–71].
EZH2 expression can determine the lineage of cell diﬀer-
entiation in the murine neural stem cells. Overexpression
of EZH2 promotes the oligodendrocytic diﬀerentiation and
concordantly impedes the astrocytic diﬀerentiation [72].
Therefore, epigenetics cannot only be an important factor
to maintain pluripotency but also determine the cell fate. If
we use this epigenetic eﬀect on diﬀerentiation of ES cells, we
will be able to establish more eﬃcient and stable cell lines
for treatment. In fact, recently reported studies found that
histone deacetylase inhibitor, sodium butylate, has an eﬀect
for improvement of the neural diﬀerentiation induction
from murine ES cells [73, 74].
6. Recent Advance of PersonalizedTherapies
Using Pluripotent Stem Cells
Use of pluripotent stem cells in personalized therapies has
made rapid progress to practical application accumulating
growing evidence in diﬀerent pathophysiological conditions
in small and larger animal models. Clinical trials are a
major step in the development of personalized stem cell
therapies into practical application. As of 30, June, 2011,
there are 3604 ongoing clinical trials of stem cells world-
wide (http://www.clinicaltrial.gov/). Although the number
of clinical trials using human pluripotent stem cells is only
limited to two, however, recent approval of the human
pluripotent stem cell clinical trials provides new prospects
for cell replacement strategies in a broad spectrum of human
neurological disorders. The Geron Corporation has initiated
the ﬁrst clinical trials of an ES cell-based therapy on human.
This study will evaluate the drug GRNOPC1, ES cell-derived
oligodendrocyte progenitors, on patients with acute spinal
cord injury. Consequently, Advanced Cell Technology has
secured FDA clearance to proceed with two separate Phase
1/2 clinical trials to test the safety of the hES cell-derivedJournal of Biomedicine and Biotechnology 5
retinalpigmentepithelial(RPE)cellulartherapyforDryAge-
Related Macular Degeneration and for Stargardt’s Macular
Dystrophy.
Although it is sure that the clinical trials of hES cell-
derived therapy will strengthen possibility of personalized
therapies using pluripotent stem cells in practical applica-
tion, however, immunological diversity of human leukocyte
antigens (HLAs) is a problem remained. As already men-
tioned, patient-speciﬁc iPS cells have many hurdles to get
over for practical application to human body such as tumor
formation and possible immune rejection mediated by aber-
ration of genetic integrity. Expanding an allogeneic pool of
in high-standard “clinical grade” hES cell lines established at
utmost ethical mandate might be a way to accelerate clinical
application of personalized pluripotent stem cell therapies
by increasing chances to ﬁnd HLA-matched cell source [75–
77]. As an eﬀort, there are increasing needs for pluripotent
stem cell registry and banking worldwide and the number
of them is being increased [78–81]. There are a number of
well-organized pluripotent stem cell registries running based
on government worldwide such as NIH Human Embryonic
Stem Cell Registry (http://escr.nih.gov), European Embry-
onic Stem Cell Registry (http://www.hescreg.eu/), and Korea
Stem Cell Registry (http://kscr.nih.go.kr/). The International
Stem Cell Banking Initiative (ISCBI) is a global network of
stem cell banks that aims to facilitate practical application
of stem cell research by harmonizing stem cell banking on a
global level [78, 79]. It is expected that the pluripotent stem
cell-based personalized therapies will be strengthened by
international collaboration, harmonization, and standard-
ization for establishment, characterization, and qualiﬁcation
of the pluripotent stem cell as well as diﬀerentiation into
functional tissues. Moreover, convergence of cutting-edge
sciences such as systems biology and informatics approaches
into pluripotent stem cell registries and banking will be
needed for further enhancement of personalized therapeutic
application of pluripotent stem cells.
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